1. Home
  2. LILA vs NVAX Comparison

LILA vs NVAX Comparison

Compare LILA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd.

LILA

Liberty Latin America Ltd.

HOLD

Current Price

$7.55

Market Cap

1.5B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$10.18

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILA
NVAX
Founded
2017
1987
Country
Bermuda
United States
Employees
10000
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
LILA
NVAX
Price
$7.55
$10.18
Analyst Decision
Strong Buy
Hold
Analyst Count
1
9
Target Price
$13.00
$11.33
AVG Volume (30 Days)
222.0K
3.6M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
64.69
52 Week Low
$4.81
$6.20
52 Week High
$9.04
$11.85

Technical Indicators

Market Signals
Indicator
LILA
NVAX
Relative Strength Index (RSI) 38.15 72.35
Support Level $7.37 $7.75
Resistance Level $8.24 $10.42
Average True Range (ATR) 0.37 0.51
MACD -0.08 0.23
Stochastic Oscillator 31.85 81.09

Price Performance

Historical Comparison
LILA
NVAX

About LILA Liberty Latin America Ltd.

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: